West Virginia has picked Humana Inc. to continue providing health insurance for the 54,000 retirees eligible for Medicare and their dependents in the state. The state’s public employees’ insurance agency awarded the health provider a new, four-year contract last week. "We value the relationship we have built with the Humana team over the past 11 years," the head of the agency, Ted Cheatham, said in a statement. "The personal approach that Humana brings will allow us to ensure the health and well-being of our retirees for years to come."
The U.S. Supreme Court on Monday declined to hear a bid by health insurance companies to seek a full reimbursement from the federal government under a provision of the Obamacare law aimed at encouraging them to offer medical coverage to uninsured Americans.
Medicaid payments are like starvation wages for doctors and hospitals. But to insurers, the government-paid health insurance for low-income families is a feast worth fighting over. Pennsylvania is trying for the third time since 2015 to replace its Medicaid contracts — worth a total of $65 billion over the last five years — with companies that manage physical health benefits for 2.6 million Pennsylvanians.
If you want to sue your health insurance company in federal court because they denied your claim or they’re not paying your medical bills in a timely fashion, chances are you can’t. But some Democrats want to change that.
The public option insurance plan has fallen off the national radar, despite being a major point of contention between moderates and progressives just a year ago during President Biden's campaign.
The seller of the brain-cancer drug Gleostine has pulled out of a federal discount program for Medicare patients, leaving some struggling to pay for a therapy that can cost as much as $1,000 per capsule. NextSource Biotechnology LLC’s decision to leave the program, rendering its drug ineligible for the Medicare Part D drug benefit, comes after the Miami company raised the drug’s price exponentially since acquiring rights in 2013. Gleostine, which treats a tumor known as glioblastoma and other brain cancers, is off-patent but has no generic alternative.